Medications Updated During January 2017, From Oldest to Newest

Page 1 of 44 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

Nystatin and Triamcinolone Acetonide

Nystatin and Triamcinolone Acetonide Ointment is indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few…

RICONPHARMA LLC1 January 2017

Zileuton

Zileuton tablets is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. CONTRAINDICATIONS: Zileuton tablets are contraindicated in patients with: Active liver disease or transaminase…

Aristos Phamaceuticals, Inc.1 January 2017

Mirtazapine

Mirtazapine orally disintegrating tablets are indicated for the treatment of major depressive disorder. The efficacy of mirtazapine tablets in the treatment of major depressive disorder…

Amneal Pharmaceuticals of New York LLC1 January 2017

Nitrofurantoin Macrocrystals

Nitrofurantoin Capsules USP (Macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci. Staphylococcus aureus, and certain susceptible strains of…

Teva Pharmaceuticals USA, Inc.2 January 2017

Riluzole

Riluzole tablets USP are indicated for the treatment of amyotrophic lateral sclerosis (ALS).Riluzole is indicated for the treatment of amyotrophic lateral sclerosis (ALS) (1) 2 DOSAGE AND ADMINISTRATION The recommended dosage for riluzole is 50 mg…

Sun Pharmaceutical Industries Limited 2 January 2017

Page 1 of 44 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

FDA Medwatch

Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid® (Thyroid Tablets, USP) Due to Super Potency
Thu, 21 May 2020. Acella Pharmaceuticals, LLC is voluntarily recalling a total of 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid® (thyroid tablets, USP) to the consumer level. The products are being recalled because our testing has found these lots to be superpotent…
Biota Biosciences Issues Voluntary Nationwide Recall of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables Because They Were Marketed Without FDA Approval
Tue, 19 May 2020. Biota Biosciences is voluntarily recalling the following lots in the table below of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables to the customer level.

MedLibrary.org

Medication Sections

RSS Feeds

About

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.